Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Here's Why Investors Should Retain Accuray (ARAY) Stock Now
by Zacks Equity Research
A series of software upgrades is likely to provide Accuray (ARAY) a competitive edge in the radiation-oncology space.
Bruker (BRKR) Q4 Earnings In Line, Margin Growth Strong
by Zacks Equity Research
Bruker (BRKR) witnesses a sturdy organic revenue uptick riding on the strength of Bruker Scientific Instruments (BSI) and BEST segments.
Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock
by Zacks Equity Research
IDEXX (IDXX) continues to demonstrate solid growth globally, with strong international expansion.
STERIS (STE) Q3 Earnings In Line, Revenues Beat Estimates
by Zacks Equity Research
STERIS (STE) continues to gain from strength in all business segments in Q3.
Here's Why Momentum Investors Will Love Abbott (ABT)
by Zacks Equity Research
Does Abbott (ABT) have what it takes to be a top stock pick for momentum investors? Let's find out.
IRADIMED (IRMD) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
IRADIMED (IRMD) reports growth across all operating segments and geographies
Here's Why You Should Buy Wright Medical (WMGI) Stock Now
by Zacks Equity Research
A growing orthopedic market and strong international expansion make Wright Medical (WMGI) a promising investment pick at the moment.
Top Ranked Momentum Stocks to Buy for February 11th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 11th:
Phirbo (PAHC) Q2 Earnings Lag Estimates, Operating Margin Up
by Zacks Equity Research
Phirbo (PAHC) witnesses significant growth in core segment revenues in Q2.
Omnicell (OMCL) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Omnicell (OMCL) steadily benefits from product introductions, strategic alliances and digital conversions.
Here's Why You Should Invest in Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker's (SYK) strong guidance for the first quarter of 2019 buoys optimism in the stock.
Here's Why You Should Invest in McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson's (MCK) solid prospects in the pharmaceutical and medical supplies distribution market look promising.
Here's Why You Should Hold Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical's (ISRG) solid exposure to robotics & medical mechatronics is commendable. Its robot-based da Vinci Surgical System for minimally-invasive surgery is an added positive.
Surmodics (SRDX) Q1 Earnings & Revenues Beat, Guidance Solid
by Zacks Equity Research
Surmodics' (SRDX) fiscal Q1 sees solid contributions from all segments.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $69.69, moving +0.93% from the previous trading session.
Here's Why You Should Snap Up Abbott (ABT) Stock Right Now
by Zacks Equity Research
We are optimistic about the strong and consistent performance of Abbott's (ABT) EPD segment. The company's Diabetes Care business has been hogging the limelight on strength in FreeStyle Libre.
Abbott (ABT) Upgraded to Buy: Here's Why
by Zacks Equity Research
Abbott (ABT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Company News For Jan 24, 2019
by Zacks Equity Research
Companies In The News Are: KMB,ABT,SYF,WMT,QSR
Abbott (ABT) Q4 Earnings Meet Estimates, Organic Growth Solid
by Zacks Equity Research
Within Structural Heart, growth is driven by several product areas across Abbott's (ABT) broad portfolio.
Abbott (ABT) Meets Q4 Earnings Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 0.00% and -0.29%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stocks' Earnings on Jan 23: ABT, NXGN & VAR
by Zacks Equity Research
Let's take a look at the factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.
Can Medical Devices Strength Drive Abbott (ABT) Q4 Earnings?
by Zacks Equity Research
Abbott (ABT) Q4 results likely to show continued growth in Medical Devices business.
Is a Surprise Coming for Abbott (ABT) This Earnings Season?
by Zacks Equity Research
Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What Lies Ahead for Abbott (ABT) Stock This Earnings Season?
by Zacks Equity Research
Abbott (ABT) is showing a steady rise on a healthy growth graph within its Diabetes Care business for a considerable period.
3 Weight-Loss Stocks in Focus on Rising Obesity Fears
by Sreyoshi Mukherjee
Three companies with bright prospects as the U.S. weight-loss industry keeps up its battle against obesity.